Mounjaro: The first GIP & GLP-1 receptor agonist for T2D treatment

Introduction

To explore the first and only GIP & GLP-1 receptor agonist for T2D management

Objectives

the first GIP & GLP-1 receptor agonist through an engaging discussion with investigators covering MoA, Phase III SURPASS trial program and appropriate patient.

This Course For :

Physician ( Endocrinology & Metabolism , Family Medicine , Internal Medicine , General practitioner )
Resident / Fellow ( Endocrinology & Metabolism , Family Medicine , Internal Medicine , General practitioner )

Speaker

Price

Course Fee

FREE

FREE
See Registration Policies, Cancellations & Refunds

Contact Information

Organization : Virtual Medical Academy
Phone : 920008161
Email : [email protected]

  • 05 Jul 2023    To    05 Jul 2023
  • 09:00 PM  To  10:00 PM
  • Certificate Available
  • Online Click Here
  • 905
  Add to Calendar 07/05/2023 09:00 PM 07/05/2023 10:00 PM Asia/ Riyadh Mounjaro: The first GIP & GLP-1 receptor agonist for T2D treatment Mounjaro: The first GIP & GLP-1 receptor agonist for T2D treatment https://medicalacademy.org/portal/event/view/1983
Mounjaro: The first GIP & GLP-1 receptor agonist for T2D treatment